Although stable mixed-hematopoietic chimerism induces robust immune tolerance to solid organ allografts in mice, the translation of this strategy to large animal models and to patients has been challenging. We have previously shown that in MHCmatched nonhuman primates (NHPs), a busulfan plus combined belatacept and anti-CD154-based regimen could induce long-lived myeloid chimerism, but without T cell chimerism. In that setting, donor chimerism was eventually rejected, and tolerance to skin allografts was not achieved. Here, we describe an adaptation of this strategy, with the addition of lowdose total body irradiation to our conditioning regimen. This strategy has successfully induced multilineage hematopoietic chimerism in MHC-matched transplants that was stable for as long as 24 months posttransplant, the entire length of analysis. High-level T cell chimerism was achieved and associated with significant donor-specific prolongation of skin graft acceptance. However, we also observed significant infectious toxicities, prominently including cytomegalovirus (CMV) reactivation and end-organ disease in the setting of functional defects in anti-CMV T cell immunity. These results underscore the significant benefits that multilineage chimerism-induction approaches may represent to transplant patients as well as the inherent risks, and they emphasize the precision with which a clinically successful regimen will need to be formulated and then validated in NHP models.
Introduction
One of the prevailing hypotheses in the field of solid organ transplantation is that if stable mixed chimerism could be reproducibly induced, then immune tolerance to both skin and solid organ allografts from the same donor would follow. In murine models, this strategy has met with widespread success (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . The critical importance of attaining and maintaining multilineage chimerism for tolerance induction has also been demonstrated in mice, where it has been shown that in the absence of T cell chimerism, tolerance induction could not be achieved (15, 16) . The significance of T cell chimerism to multilineage donor allogeneic hematopoietic cell chimerism stability has also been observed in clinical transplantation, where patients who lack substantial (>50-75%) donor T cell engraftment even in the setting of significant myeloid chimerism are at high risk for loss of the donor hematopoietic graft (17) (18) (19) (20) . Although the mechanisms controlling T cell chimerism-mediated tolerance are not completely understood, they likely include the migration of both donor T cells and T cell precursors to the thymus to promote central tolerance (15, 16, 21) .
Though chimerism-based strategies for tolerance induction have achieved widespread success in mice, the translation of the intentional induction of stable multilineage mixed chimerism to nonhuman primate (NHP) models and to the clinic has been more challenging. This is especially the case after lower intensity nonmyeloablative pretransplant conditioning, with most work focused on inducing transient chimerism (16, (22) (23) (24) (25) (26) . Alternatively, others have chosen to significantly escalate the intensity of pretransplant conditioning to establish the donor graft (27) (28) (29) (30) or to induce fulldonor rather than mixed chimerism (31) (32) (33) . Our group has built on our experience with reduced-intensity pretransplant conditioning and T cell costimulation-blockademediated chimerism and tolerance induction in mice (1) (2) (3) 5, 6) as the platform for translation to NHPs. Using an MHC-defined NHP model, we first sought to determine whether we could directly translate the success in mice, using a busulfan-based conditioning regimen and either anti-CD154 or anti-CD40 antibodies plus CD80/CD86-directed costimulation blockade-based immunomodulation, to NHPs. Our previous work demonstrated the successful induction of long-lived (>1 year) myeloid-predominant chimerism with this regimen (1, (34) (35) (36) (37) . However, unlike in mice, reduced-intensity busulfan-only conditioning in NHPs did not lead to significant T cell chimerism (34, 35) , and without significant T cell chimerism, the donor hematopoietic graft was eventually rejected by host T cells (34, 35, 38) (at a pace directly related to the degree of MHC disparity) (35) . This transient chimerism did not induce tolerance to renal allografts (37) . Here, we report an adapted transplant strategy that can lead to long-lived multilineage mixed chimerism, and in the setting of significant T cell chimerism, that is associated with tolerance to donor hematopoiesis and prolonged skin graft acceptance. However, these transplants also provide an important cautionary tale: this tolerance-induction regimen was associated with a significant risk of infectious disease complications (prominently including cytomegalovirus [CMV] reactivation and disease), along with evidence for functional deficits in antiviral protective immunity. Further refinements of this transplant strategy designed to "thread the needle" of allograft tolerance while maintaining intact protective immunity are needed for successful translation to the clinic.
Materials and Methods

Experimental animals
This study used Indian-origin rhesus macaques (18 animals) from the Yerkes National Primate Research Center, the Washington National Primate Research Center and the National Institutes of Health (NIH)-sponsored rhesus macaque colony operated by Alphagenesis Inc. The study was conducted in strict accordance with US Department of Agriculture (USDA) regulations and the recommendations in the Guide for the Care and Use of Laboratory Animals. It was approved by both the Emory University and the University of Washington Institutional Animal Care and Use Committees.
MHC typing
Details of the MHC typing and disparity between donors and recipients are described in detail in Supplementary Methods.
Transplant preparation and immunosuppression strategy
The transplant strategy is shown in Figure 1 and is based on our previously published costimulation-blockade-based immunosuppression strategy (34, 35) , with the addition of low-dose (200 or 300 cGy) total body irradiation (TBI; delivered with a linear accelerator [Varian] at a dose-rate of ≤7 cGy/min) to the busulfan-based pretransplant conditioning regimen. Details of the strategy and dosing regimens are described in Supplementary Methods.
Hematopoietic stem cell transplant protocol
Hematopoietic stem cell transplant (HCT) utilized leukopheresis-derived hematopoietic stem cells (HSCs), harvested using a COBE Spectra or Spectra Optia apparatus (Terumo BCT, Inc., Lakewood, CO) from donors that underwent granulocyte colony-stimulating factor (G-CSF)-based mobilization (50 mcg/kg 9 5 days subcutaneously), as previously described (34, 35) . The total nucleated cell dose/kg, total CD3 + T cell dose/kg and total CD34 + cell dose/kg for each transplant recipient is shown in Table 1 .
Chimerism determination
Bone marrow, whole blood and flow-cytometry-sorted myeloid cells (CD3
were analyzed for donor chimerism based on divergent microsatellite markers at the UC Davis veterinary genetics laboratory, as previously described (34, 35) .
CMV monitoring, primary prophylaxis and treatment CMV monitoring, primary prophylaxis and treatment are described in Supplementary Methods.
ELISPot analysis of CMV-specific T cell immunity
Enzyme-linked immunospot (ELISPot) analysis was performed as previously described and detailed in Supplementary Methods.
Longitudinal flow cytometric analysis of T cell phenotype
Immune cell subpopulations were quantified flow cytometrically as previously described (details supplied in Supplementary Methods).
Skin allografting
Details of skin allografting are supplied in the Supplementary Methods.
Statistical analysis
Analysis of variance (ANOVA) and Kaplan-Meier analysis were carried out using GraphPad Software version 6 (GraphPad, La Jolla, CA). To determine ANOVA for multiple parameters, a post hoc Tukey honest significant difference (HST) test was used to determine significant differences for pair-wise comparisons.
Results
Multilineage mixed chimerism in NHPs
In this study we designed a stringent multiyear transplant protocol using MHC-matched transplant pairs (Table 2) , in which our previously published busulfan/ costimulation blockade/sirolimus-based regimen (34, 35) was modified to enhance donor lymphoid chimerism (39) with low-dose (200-300 cGy) TBI (40) (41) (42) . As shown in Figure 1 , completion of the entire experimental protocol required at least 25 months of follow-up: This included a pretransplant conditioning phase (2 weeks) and ontherapy phase (10 months) during which recipients were first conditioned with nonmyeloablative doses of busulfan + TBI, and then treated with sirolimus/5C8/ belatacept, followed by sequential discontinuation in the following order: sirolimus?5C8?belatacept. After all immunosuppression was weaned, recipients were monitored for at least 12 months for chimerism stability, followed by skin allografting. As shown in Figures 2(A) and (B), this conditioning regimen in conjunction with costimulation blockade/sirolimus-based posttransplant immunosuppression was successful in creating multilineage chimerism in all transplant recipients. However, only 3 of the 9 transplanted animals completed the entire transplant protocol; the remaining animals reached protocol endpoint criteria due to clinical evidence of disease not responsive to treatment (on days 32-202 posttransplant), each with infectious toxicities (discussed in detail below). For 2 of the 3 surviving animals, R.51 and R.52, multilineage mixed chimerism was sustained for the entire experiment. For the third transplant recipient, R.53, who received a substandard dose of donor cells after a problematic apheresis procedure (including a~10-fold lower dose of total nucleated cells [TNCs] CD34+ and CD3+ cells; Table 1 ), the initial chimerism set point was substantially lower compared with those of the other recipients (27% bone marrow [BM] chimerism at day +30 compared to 88% AE 8.8% in the remaining 8 animals; Figure 2A ). As shown in Figure 2 , sirolimus (once daily dosing was begun at 0.025 mg/kg and adjusted to achieve a serum trough level of 10-15 mg/mL). Autologous and donor skin grafts were placed as shown. Third-party grafts were placed approximately 150 days after the placement of the donor and autologous skin grafts. TBI, total body irradiation. MDR E. coli end-organ failure Table 2 : Microsatellite-based typing of transplant donors and recipients. Individual MHC haplotypes are color coded
COLOR
High incidence of CMV reactivation and other infectious disease complications amid defects in antiviral T cell function Although the creation of multilineage mixed chimerism that was capable of lasting longer than 2-3 years (Figure 2B ) is a striking result, one of the most important observations made in this study was the high incidence of infections that occurred. As shown in Table 1 and Figure 3 , transplant recipients all experienced serious infectious disease complications. These prominently included CMV reactivation and disease (despite the fact that all recipients received primary prophylaxis and secondary CMV treatment using a regimen that has successfully prevented high-level CMV reactivation and disease in our other NHP studies) (35) but also included bacterial complications, including Giardia enterocolitis, Bacillus bacteremia and multi-drug-resistant Escherichia coli bacteremia. To quantify the impact of the transplant regimen on T-cell-mediated anti-CMV immunity, we used ELISpot assays (Monkey IFN-c ELISpot Basic kit from Mabtech, Cincinnati, OH) directed at CMV antigens in 8 animals for which we had available samples. These pretransplant. It is important to note that the necropsy samples for the sick animals (R.55 and R.58) were obtained when they were still on immunosuppression, while the necropsy samples from R.51 and R.53 were obtained after immunosuppression withdrawal but with ongoing mixed chimerism.
Impact of sirolimus and costimulation blockade on hematologic reconstitution after transplantation
To investigate the hematologic associations with transplant course, a detailed longitudinal investigation of immune reconstitution was performed. Figure 5 shows the white blood cell (WBC) count, absolute neutrophil count (ANC) and absolute lymphocyte count (ALC) for all recipients. These data demonstrate that generalized lymphopenia developed and persisted in the setting of triple immunosuppression with sirolimus/5C8/ belatacept. Whereas the high risk of infectious complications led to early experimental termination in 6 recipients, as noted above, 3 animals (R.51, R.52, and R.53) were evaluable for the entire 25-month experiment. In each of these recipients, lymphopenia persisted after sirolimus withdrawal (during continued costimulation blockade with 5C8 and belatacept) and continued until discontinuation of 5C8, at which time there was a significant increase in lymphocyte counts, despite ongoing treatment with belatacept. There were no further increases in total lymphocyte counts when belatacept was discontinued. in both CD4 + and CD8 + T cell counts significantly rebounding, with no further increase after the discontinuation of belatacept ( Figure 6A ). The withdrawal of sirolimus and 5C8 also resulted in a significant shift in the T cell subset balance, with a shift in the proportion of both CD4 and CD8 T cell subsets away from the CD28 + /CD95 À na€ ıve phenotype ( Figure 6B ). In CD4 + T cells, this was accompanied by both a proportional and absolute expansion of CD28 + /CD95 + central memory T cells (Tcm). In CD8+ T cells, the loss of the T-na€ ıve phenotype was accompanied by a significant shift toward both CD28 + /CD95 + Tcm and CD28 À /CD95 + effector memory (Tem) phenotype, with Tcm > Tem expansion. As shown in Figures 6(A) and (B), discontinuation of belatacept and, thus, the total withdrawal of all maintenance immunosuppression resulted in no further shift in subpopulation balance or further expansion of conventional T cell numbers. Analysis of regulatory T cell (Treg) homeostasis demonstrated a different pattern, with a proportional drop in these cells after withdrawal of sirolimus and 5C8, which did not recover until withdrawal of belatacept ( Figure 6C) . Moreover, the absolute number of Tregs did not significantly expand until after triple immunosuppression withdrawal.
Development of graft-versus-host disease in R.52 Though none of the other animals in this study developed clinically apparent graft-versus-host disease (GVHD), on day 255 posttransplant, animal R.52 developed a skin rash covering 60% of his body surface area (BSA), that, when biopsied, showed histologic evidence of GVHD. This animal had previously experienced an episode of vomiting for which GVHD was considered in the differential diagnosis, but he developed neither diarrhea nor hyperbilirubinemia posttransplant. The diagnosis of GVHD prompted us to treat this recipient with oral prednisone from day 271 to day 550 posttransplant (with weaning and full discontinuation of prednisone prior to skin graft placement). Of note, T cell chimerism was stable prior to, during and after the development and treatment of R.52 for GVHD (see Figure 2B ).
Prolongation of donor skin graft acceptance in transplant recipients with significant T cell chimerism
The survival of R.51, R.52, and R.53 to the 2+ year experimental endpoint allowed us to test the impact of T cell chimerism on skin graft survival. We had tested this on a previously reported animal (RQq9, conditioned with busulfan alone, without concomitant TBI), who had developed very low T cell chimerism and who had demonstrated donor skin graft rejection within 30 days (35) . As shown in Figure 7 , in the current study, we observed a direct relationship between the percent T cell chimerism and the length of skin allograft survival. Thus, as shown in Figure 7 (A), R.51, who demonstrated stable, high-level T cell chimerism (~70% at the time of skingraft placement), demonstrated long-term acceptance of both autologous and donor skin (>100 days) despite rapid rejection of unrelated, third-party skin (rejection by 9 days post-skin-graft placement; Figure 7A ). R.51 is thus the first NHP in our experience to meet the formal definition of long-term stable multilineage mixedchimerism and donor-specific tolerance, having maintained mixed donor-recipient hematopoiesis for over 700 days and donor-specific acceptance of skin allografts for over 100 days.
R.52, who demonstrated significant levels of T cell chimerism, but at levels lower than in R.51, also demonstrated significant prolongation of donor skin graft acceptance. In this recipient, third-party skin was rejected promptly (9 days), and donor skin was accepted for significantly longer (~69 days; Figure 7B ). Importantly, however, R.52 eventually rejected the donor skin, and autologous skin was accepted long term. It should be noted, as discussed above, that R.52 was also the animal who developed skin GVHD.
Recipient R.53, who lost donor chimerism prior to skin graft placement, showed rejection of the donor skin graft at a similar tempo to previous recipients who had never developed T cell chimerism, showing signs of rejection by day 40 post-skin-graft placement ( Figure 7C ). This observation is important because it provides evidence to support the hypothesis that significant T cell chimerism, rather than the conditioning regimen (which was identical in R.51, R.52, and R.53), was associated with skin graft tolerance.
Of note, a fourth recipient, RDe9, who had been previously reported as the one recipient with stable chimerism in an earlier experimental cohort not receiving TBI (35) (for whom the donor was unfortunately not available for skin grafting) has now been followed for more than 10 years posttransplant and has been a stable multilineage mixed chimera for the entire follow-up period, in the setting of substantial T cell chimerism (currently at 30%, with follow-up for >10 years; Figure 2D ). Taken together, these results are consistent with the acquisition of T cell chimerism as highly associated with longterm allograft acceptance, including both acceptance of bone marrow and skin graft tolerance.
Indeed, although the number of recipients analyzed was small, three important observations arise from the skin allograft experiments, shown in Figure 7 . First, we found that it was possible to create a scenario (R.51) in which tolerance to both bone marrow and skin was created. Second, in the 4 animals on whom skin grafts were placed (3 in the current study, 1 in a previous study [35] ), there was a direct correlation between the percent T cell chimerism and donor allograft survival ( Figure 7D ). Finally, in each of these animals, immune competence to allografts were maintained, given the rapid rejection of third-party skin in 3/3 animals tested.
Discussion
In this study, we demonstrate that a transplant strategy employing a nonmyeloablative busulfan/TBI conditioning regimen and costimulation blockade plus sirolimus-based immunomodulation can reliably produce multilineage mixed chimerism, and in the setting of substantial and stable T cell chimerism, donor-specific acceptance of a skin allograft is achievable. These results are notable, given the demonstration that stable multilineage mixed chimerism can be intentionally created in primates. This represents, to our knowledge, the longest duration of stable multilineage mixed chimerism induction in NHPs. As such, these data provide proof-of-concept that, even in outbred primates, stable T cell mixed chimerism can be achieved by design. As we will discuss in detail below, the results of this study also underscore the significant risks of infectious disease complications that can accompany this transplant regimen, indicating that further modifications are necessary before translation to the clinic.
This study is distinguished from others in the field by two facts: (1) It sought to intentionally create mixed donor/recipient T cell chimerism, and (2) create multilineage mixed chimerism that was stable posttransplant. Thus, the group at Massachusetts General Hospital (MGH) has developed a transplant regimen in NHPs that leads to transient donor chimerism, with rejection of the donor bone marrow transplant (BMT) within 1 month of transplantation (22) (23) (24) (25) (26) . In NHPs, this regimen is effective in achieving long-term renal allograft tolerance in approximately half of the renal transplant recipients. Encouragingly, clinical trials of BMT plus renal transplant based on these NHP studies resulted in multiple patients being weaned off of immunosuppression (27, 28, (43) (44) (45) . However, a significant engraftment syndrome (43) developed in several patients, suggesting that loss of the donor hematopoietic graft may have untoward effects in humans that were not observed in NHPs.
An independent clinical transplant series from the Stanford group has led to sustained donor chimerism in the setting of intensive total lymphoid irradiation (TLI; 1200 cGy) plus anti-thymocyte globulin (ATG) during combined BMT plus renal transplant. This regimen has been successful in achieving stable mixed chimerism and tolerance to the renal allograft in a number of MHCmatched donor/recipient pairs (27) (28) (29) (30) . Whether this regimen will be translatable to the more commonly encountered MHC-mismatched setting is not yet known. Finally, the Leventhal and Ildstadt group has reported full donor engraftment (ie not mixed chimerism, but rather full replacement with donor hematopoieisis) and long-term allograft acceptance in patients given combined hematopoietic and renal transplants in the presence of facilitating cells. Though this trial is not a "mixed-chimerism" trial per se, if long-term GVHD-free immunosuppression-free survival becomes a reality for these patients, it is of high significance to the field.
In the current study, by closely monitoring the impact of sequential withdrawal of sirolimus, followed by anti-CD154, followed by belatacept, we gained important insights into the impact of triple, dual and single immunomodulation on T cell reconstitution and subpopulation balance. Our results demonstrate a significant suppression of absolute T cell counts and preservation of na€ ıve T cell predominance during sirolimus and dual costimulation blockade. The suppression of T cell expansion and changes in T cell subpopulation balance were maintained despite discontinuation of sirolimus. When anti-CD154 treatment was also discontinued (during monotherapy treatment with belatacept), we observed both T cell expansion and a shift in the subpopulation balance, from a Tnaive predominance to a Tcm predominance for both CD4 and CD8 T cells (with CD8 T cells also expanding the Tem compartment). Importantly, although no further quantitative or qualitative changes occurred in the conventional T cell compartment after withdrawal of belatacept, discontinuation of this therapy was associated with expansion of Tregs. The shift in CD8+ T cells to a Tcm (rather than a Tem) predominance is a new finding that we have not observed with our previous mixed-chimerism experiments (34) (35) (36) (37) . Although this, along with the eventual expansion of Tregs is notable, it is not clear whether these shifts represent causation or correlation with tolerance induction. As such, this represents an important area for future study. Importantly, these data also indicate that reciprocal tolerance to both donor and recipient hematopoiesis could persist despite both the T cell expansion and the shift in the na€ ıve/memory T cell balance that occurred after immunosuppression withdrawal, indicating robust control of both host-versus-graft and graft-versus-host vectors of T cell activation toward hematopoiesis with this transplant strategy.
The stability of bidirectional tolerance to hematopoiesis (permitting the coexistence of both donor and recipient T cells) also suggests that central tolerance mechanisms contributed to long-term acceptance of the hematopoietic graft in this model. The observation of donor chimerism in 3 of 4 isolated thymi is supportive of this hypothesis ( Figure 2C ). The significant duration of triple?double?single agent immunomodulation (with some form of immunosuppression present for 300 days posttransplant) may have facilitated the development of central tolerance, by providing sufficient immunosuppression-mediated immune restraint to permit trafficking of donor cells to the thymus.
One of the other central experiments performed in this transplant series was the placement of autologous, donor and nondonor "third-party" skin allografts a full year after withdrawal of sirolimus and costimulation blockade. This experiment demonstrated long-term acceptance (>100 days) in the recipient with the highest level of T cell chimerism, prolonged but limited skin graft acceptance in a recipient with lower but still significant T cell tolerance and prompt rejection of donor skin in two recipients with no T cell chimerism. These data suggest that, as in mice, in primates tolerance to tissues may require significant, stable T cell chimerism. One important caveat to the current studies is the well-recognized "high bar" for tolerance induction that skin grafts represent. It is possible that less immunogenic grafts, such as renal or liver allografts, could have a lower threshold for T cell chimerism required for tolerance induction. Indeed, we also observed GVHD of the skin in R.52, which, though reversible with steroids, suggests that the difficulty in attaining tolerance to skin antigens occurred in both the host-versus-graft and the graft-versus-host directions in this animal. Renal allograft studies (both proof-of-concept delayed renal transplantation as well as renal allografts placed concurrently with chimerism induction) thus represent an important area for future research, once an optimized regimen, able to support stable mixed chimerism while minimizing infectious complications, is developed.
Despite the success in creating donor chimerism that was capable of lasting for several years, the extremely high rate of loss of our transplant recipients due to infectious disease complications represents a sobering reality. In the current study, 8/9 recipients experienced CMV reactivation, despite all recipients receiving primary prophylaxis with cidofovir. In 2 of these recipients, CMV end-organ disease was associated with recipient death, underscoring the seriousness of CMV disease in this transplant regimen and the difficulty of reversing CMV disease in NHPs, a phenomenon that has been documented previously by our group and others (34, 35, (46) (47) (48) (49) (50) (51) . Whether the clinical challenges encountered with this virus are an inherent attribute of the NHP-specific CMV virus or due to decreased efficacy of standard antivirals against rhesus CMV is not known. Delivering effective treatment for CMV is also considerably more challenging in NHPs than in patients, which could also have negatively affected our ability to control reactivated virus. Importantly, the most significant infectious disease complications occurred during the period of active immunosuppression, rather than during the period of sustained mixed chimerism, with R.52 and R.53 being much more stable from an infectious disease standpoint after immunosuppression withdrawal than they were on triple-, double-, or single-agent therapy. This observation suggests that a rigorous step-wise elimination experiment is warranted to determine which elements of the conditioning regimen and immunomodulatory strategy are required for stable multilineage mixed chimerism and which produce the most severe functional defects in protective immunity. If successful, this approach may yield a regimen that can succeed in producing tolerance without the defects in protective immunity observed in this transplant series. Although it is not yet clear which of the elements of pretransplant conditioning or posttransplant immunomodulation are the most important to eliminate or alter, our results suggest that a regimen that drives less severe lymphopenia while maintaining a positive Treg:Tcon balance would potentially tip the balance in favor of specific tolerance to the donor with less global defects in antiviral protective immunity.
In summary, this transplant series has demonstrated a series of important milestones as well as challenges to tolerance induction. We describe a transplant regimen that is consistently able to induce multilineage mixed chimerism as well as proof-of-concept that in the setting of significant T cell mixed chimerism, donor-specific tolerance, even to a highly immunogenic skin graft, is possible. We also demonstrate an important pitfall with this regimen, encapsulated by the significant clinical risks of infectious disease-related morbidity and mortality that these transplant recipients faced. These risks provide strong rationale for further iteration of this tolerance induction strategy to identify the minimally effective immunomodulation strategy. Standing at the precipice of intentional multilineage mixed chimerism and tolerance induction, these studies underscore both the significant benefits that these approaches may represent to patients as well as the risks, and they emphasize the precision with which clinically successful regimens will need to be formulated.
